By Finny Kuruvilla, MD, PhD
Co-Chief Investment Officer, Senior Portfolio Manager, Managing Director, Founding Member
Lung cancer is the leading cause of cancer deaths in the world today.1
The standard of care for lung cancer has been a combination of surgery, chemotherapy, and radiation. But each of these therapies is fraught with significant collateral damage.
Precision oncology seeks to minimize the adverse side effects associated with surgery, chemotherapy, and radiation by offering a more targeted approach.
Listen to why we believe Precision Oncology is a compelling investment theme as Eventide CIO Finny Kuruvilla, MD, PhD, explains how treating cancers like lung cancer at the molecular level yields fewer side effects and better outcomes.
Featuring Finny Kuruvilla, MD, PhD